These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 171574

  • 1. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
    Jain AK, Ryan JR, McMahon FG.
    N Engl J Med; 1975 Dec 18; 293(25):1283-6. PubMed ID: 171574
    [Abstract] [Full Text] [Related]

  • 2. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
    Kudzma DJ, Friedberg SJ.
    Diabetes; 1977 Apr 18; 26(4):291-5. PubMed ID: 321288
    [Abstract] [Full Text] [Related]

  • 3. The metabolic spectrum of halofenate.
    Ryan JR.
    Int J Clin Pharmacol Biopharm; 1975 Jul 18; 12(1-2):239-43. PubMed ID: 51838
    [Abstract] [Full Text] [Related]

  • 4. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA, Azarnoff DL, Huffman DH, Pentikäinen P, Hurwitz A, Shoeman DW.
    Clin Pharmacol Ther; 1976 Mar 18; 19(3):352-9. PubMed ID: 177242
    [Abstract] [Full Text] [Related]

  • 5. A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients.
    Pedrazzi F, Bommartini F, Freddo J, Emanueli A.
    Eur J Rheumatol Inflamm; 1981 Mar 18; 4(1):26-31. PubMed ID: 7042358
    [Abstract] [Full Text] [Related]

  • 6. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J, de Neuman MP, Talmasky S, Pesce R, Valero E, Martiarena JL.
    J Cardiovasc Surg (Torino); 1973 Mar 18; Spec No():532-7. PubMed ID: 4377715
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH, Seftel HC, Joffe BI.
    S Afr Med J; 1977 Mar 12; 51(11):348-52. PubMed ID: 323994
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C, Wolfram G, Zöllner N.
    Arzneimittelforschung; 1976 Mar 12; 26(12):2221-4. PubMed ID: 798591
    [Abstract] [Full Text] [Related]

  • 10. A two-year crossover therapeutic trial with halofenate and clofibrate.
    Dujovne CA, Azarnoff DL, Pentikainen P, Manion C, Hurwitz A, Hassanein K.
    Am J Med Sci; 1976 Mar 12; 272(3):277-84. PubMed ID: 797258
    [Abstract] [Full Text] [Related]

  • 11. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T.
    Atherosclerosis; 1976 Sep 12; 24(3):537-46. PubMed ID: 788722
    [Abstract] [Full Text] [Related]

  • 12. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
    Kuntzen O, Hehl FJ, Walter E, Zimmermann R.
    Arzneimittelforschung; 1978 Sep 12; 28(12):2349-52. PubMed ID: 227420
    [Abstract] [Full Text] [Related]

  • 13. Halofenate versus clofibrate in the management of true diabetes insipidus.
    Gattereau A, Davignon J, Verdy M, Lewis W.
    Can Med Assoc J; 1974 Jun 08; 110(11):1275-77. PubMed ID: 4834432
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
    Koschinsky T, Lenhard P, Gries FA, Vogelberg KH, Wolfram G, Lang PD, Vollmar J.
    Med Klin; 1977 Sep 23; 72(38):1537-43. PubMed ID: 904549
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ, Patsch J, Sailer S, Braunsteiner H.
    Atherosclerosis; 1975 Sep 23; 21(3):391-9. PubMed ID: 1148032
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
    Schapel GJ, Edwards KD.
    J Pharmacol Exp Ther; 1975 Jul 23; 194(1):274-84. PubMed ID: 1171221
    [Abstract] [Full Text] [Related]

  • 17. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W, Kremer GJ, Müller D.
    MMW Munch Med Wochenschr; 1975 Oct 31; 117(44):1783-6. PubMed ID: 171564
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
    Loubatiéres A, Mariani MM, Ribes G, Alric R.
    Acta Diabetol Lat; 1973 Oct 31; 10(2):261-82. PubMed ID: 4200675
    [No Abstract] [Full Text] [Related]

  • 19. A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia.
    Rottiers R, van Egmond J.
    Acta Clin Belg; 1975 Oct 31; 30(5):398-408. PubMed ID: 1221746
    [No Abstract] [Full Text] [Related]

  • 20. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
    Aronow WS, Vangrow JS, Nelson WH, Pagano J, Papageorge's NP, Khursheed M, Harding PR, Khemka M.
    Curr Ther Res Clin Exp; 1973 Dec 31; 15(12):902-6. PubMed ID: 4203573
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.